<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="102094"><DrugName>rostaporfin (PDT, cutaneous metastatic cancers/basal cell nevus syndrome), Adgero Biopharmaceuticals</DrugName><DrugNamesKey><Name id="43120677">rostaporfin</Name></DrugNamesKey><DrugSynonyms><Name><Value>tin ethyl etiopurpurin dichloride</Value></Name><Name><Value>tin etiopurpurin dichloride</Value></Name><Name><Value>REM-001 therapy</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>rostaporfin (PDT, cutaneous metastatic cancers/basal cell nevus syndrome), Adgero Biopharmaceuticals</Value></Name><Name><Value>rostaporfin</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>REM-001</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>284041-10-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1124232">Adgero Biopharmaceuticals Holdings Inc</CompanyOriginator><CompaniesPrimary><Company id="1124232">Adgero Biopharmaceuticals Holdings Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1124232" type="Company"><TargetEntity id="5047645538" type="organizationId">Adgero Biopharmaceuticals Holdings Inc</TargetEntity></SourceEntity><SourceEntity id="1069" type="ciIndication"><TargetEntity id="10062194" type="MEDDRA"/><TargetEntity id="D009362" type="MeSH"/><TargetEntity id="-1423187778" type="omicsDisease"/><TargetEntity id="618" type="siCondition"/></SourceEntity><SourceEntity id="1765" type="ciIndication"><TargetEntity id="D018281" type="MeSH"/><TargetEntity id="70567" type="ORPHANET"/><TargetEntity id="-2122101383" type="omicsDisease"/><TargetEntity id="1844" type="siCondition"/></SourceEntity><SourceEntity id="3382" type="ciIndication"><TargetEntity id="10062804" type="MEDDRA"/><TargetEntity id="D001478" type="MeSH"/><TargetEntity id="377" type="ORPHANET"/><TargetEntity id="-1429179473" type="omicsDisease"/><TargetEntity id="1683" type="siCondition"/></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"/><TargetEntity id="589" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1069">Metastasis</Indication><Indication id="1765">Cholangiocarcinoma</Indication><Indication id="3382">Basal cell nevus syndrome</Indication><Indication id="3657">Metastatic breast cancer</Indication></IndicationsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="799">Photosensitizer</Action></ActionsSecondary><Technologies><Technology id="725">Luminescence</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="599">Nanoparticle formulation injectable</Technology><Technology id="142">Liposome formulation</Technology><Technology id="1066">Phototherapy deal</Technology></Technologies><LastModificationDate>2018-10-29T09:39:30.000Z</LastModificationDate><ChangeDateLast>2018-10-30T00:00:00.000Z</ChangeDateLast><AddedDate>2016-05-23T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1124232" linkType="Company"&gt;Adgero Biopharmaceuticals&lt;/ulink&gt;, following acquisition in 2012 of assets previously developed by &lt;ulink linkID="21714" linkType="Company"&gt;Miravant Medical Technologies&lt;/ulink&gt; (which was at that time no longer trading), is developing REM-001 therapy, consisting of a laser light source, a light delivery device and the photosensitizer drug &lt;ulink linkID="10564" linkType="Drug"&gt;rostaporfin&lt;/ulink&gt; (tin ethyl etiopurpurin dichloride), for the potential treatment of cutaneous metastatic breast cancer (CMBC), and other cutaneous metastatic cancers including lung, colon and ovarian,  and bile duct cancer, and basal cell nevus syndrome (BCNS) [&lt;ulink linkID="1764139" linkType="Reference"&gt;1764139&lt;/ulink&gt;], [&lt;ulink linkID="1764150" linkType="Reference"&gt;1764150&lt;/ulink&gt;], [&lt;ulink linkID="1998132" linkType="Reference"&gt;1998132&lt;/ulink&gt;]. By May 2016, the therapy had been studied in phase II/III trials for CMBC, in phase I/II trials for BCNS, and in phase I trials for other cutaneous metastatic cancers and bile duct cancer [&lt;ulink linkID="1764139" linkType="Reference"&gt;1764139&lt;/ulink&gt;]. In October 2018, this was still the case [&lt;ulink linkID="2087660" linkType="Reference"&gt;2087660&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By May 2016, the company had planned to file for Orphan Drug designation and Breakthrough Therapy designation [&lt;ulink linkID="1764150" linkType="Reference"&gt;1764150&lt;/ulink&gt;]. In January 2018, the US FDA granted tin ethyl etiopurpurin Orphan designation for treatment of basal cell carcinoma nevus syndrome (BCCNS) [&lt;ulink linkID="1998127" linkType="Reference"&gt;1998127&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By May 2016, in four phase II/III trials in 148 patients with CMBC who had failed radiation therapy, REM-001 had demonstrated safety and efficacy, and had shown a complete response in approximately 80% of evaluable  tumor sites. In  patients who had failed standard care therapy, REM-001 demonstrated a high response rate and was well tolerated [&lt;ulink linkID="1764139" linkType="Reference"&gt;1764139&lt;/ulink&gt;], [&lt;ulink linkID="1764150" linkType="Reference"&gt;1764150&lt;/ulink&gt;]. In April 2017, positive data from retrospective analysis of all the four studies (n = 149),  were presented at the 37th American Society for Laser Medicine and Surgery Annual Conference held  in San Diego, CA. After 24 to 52 weeks follow-up, the overall response rate was 88 and 81% for patients administered with  REM-001  plus chemotherapy/hormone therapy and  REM-001 therapy alone, respectively [&lt;ulink linkID="1916974" linkType="Reference"&gt;1916974&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2018, a phase II study in patients with  basal cell carcinoma nevus syndrome  was to be initiated in 2018 [&lt;ulink linkID="2007615" linkType="Reference"&gt;2007615&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2016, data from a phase I/II study  in 14 patients with BCNS, REM-001 therapy was reported. Data demonstrated   complete response rate of 68 per cent and an overall response rate of 91 per cent [&lt;ulink linkID="1764139" linkType="Reference"&gt;1764139&lt;/ulink&gt;], [&lt;ulink linkID="1764150" linkType="Reference"&gt;1764150&lt;/ulink&gt;]&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1124232">Adgero Biopharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2016-05-19T00:00:00.000Z</StatusDate><Source id="1764139" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1124232">Adgero Biopharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3382">Basal cell nevus syndrome</Indication><StatusDate>2016-05-19T00:00:00.000Z</StatusDate><Source id="1764150" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1124232">Adgero Biopharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1069">Metastasis</Indication><StatusDate>2016-05-19T00:00:00.000Z</StatusDate><Source id="1764139" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1124232">Adgero Biopharmaceuticals Holdings Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate>2016-05-19T00:00:00.000Z</StatusDate><Source id="1764139" type="CORPORATE"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="1124232">Adgero Biopharmaceuticals Holdings Inc</OwnerCompany><Country id="US">US</Country><Indication id="3657">Metastatic breast cancer</Indication><AwardedIndication>Treatment of cutaneous metastatic breast cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="4">Planned</DesignationApplicationStatus><MileStoneDate>2016-05-19T00:00:00.000Z</MileStoneDate><Source id="1764150" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1124232">Adgero Biopharmaceuticals Holdings Inc</OwnerCompany><Country id="US">US</Country><Indication id="3382">Basal cell nevus syndrome</Indication><AwardedIndication>Treatment of basal cell carcinoma nevus syndrome (BCCNS)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-01-16T00:00:00.000Z</MileStoneDate><Source id="1998127" type="CORPORATE"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1124232">Adgero Biopharmaceuticals Holdings Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21714">Miravant Medical Technologies</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCc1c(c2/cc/3\nc(/cc\4/c(c(c5/n4[Sn](n2c1/cc/6\nc7\c5\C=C([C@@]7([C@H]6C)CC)C(=O)OCC)(Cl)Cl)C)CC)C(=C3CC)C)C</Smiles></StructureSmiles><Deals><Deal id="245533" title="Adgero acquires Miravant Medical Technologies' assets related to REM-001   "/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>